Fecobionics to Monitor and Predict Biofeedback Therapy in Dyssynergia Patients
Fecobionics to Monitor and Predict Biofeedback Therapy in Dyssynergia Patients
Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.
This study aims to monitor and predict biofeedback therapy based on mechanism-based and highly integrated data using a new medical device. This study is specifically for patients with dyssynergia before, during, and after biofeedback therapy. The balloon-like Fecobionics device (10 cm long and 1 cm in diameter) will be inserted into the participant's rectum and will record data before and during the expulsion of the device. The participant will be asked to do different motions like cough, squeeze, or push during the procedure. The novel data obtained in this study may help the investigators to identify the patients who will benefit or not benefit from biofeedback therapy before the therapy is done. This will determine the effectiveness of treatments for anorectal disorders.
Inclusion Criteria:
Exclusion Criteria:
hag@giome.org858-249-7400
srao@augusta.edu706-7212238
San Diego, California 92121, United States
hag@giome.org858-249-7400
gkassab@calmi2.org858-249-7400
srao@augusta.edu706-721-2239